Sunday, February 28, 2021
News

Avoid Covaxin in case of allergies, fever: Bharat Biotech

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

Hyderabad | Tuesday, 2021 7:15:06 PM IST
Bharat Biotech, makers of India's first indigenous vaccine for Covid-19, has advised people not to take 'Covaxin' if they have allergies, fever, bleeding disorder, are on blood thinners, immune-compromised, or are on medicines that affect immune system.

The Hyderabad-based vaccine-maker, in a fact sheet for recipients and caregivers, said that even pregnant and nursing women should not take the vaccine.

People who have taken another Covid-19 vaccine or are suffering from any other serious health-related issues should also not take Covaxin.

Bharat Biotech reiterated that the Drugs Controller General of India (DCGI) had authorised the "restricted use of Covaxin under clinical trial mode".

"Individuals who are prioritised under the public health programme of the Health Ministry will be covered under this endeavour. Informing the individuals about the offer to vaccinate them with Covaxin will rest with the respective government programme officials. Those offered Covaxin at pre-specified booths will have the option to receive or reject the administration of the vaccine," says the fact sheet that surfaced on Tuesday.

Company sources told IANS that the fact sheet was issued last week.

"As with any new medicine, this vaccine will be closely monitored to allow quick identification of any new safety information," said Bharat Biotech. Side effects can be reported to toll-free number 18001022245.

The vaccine-maker said that in phase 1 and 2 clinical trials, Covaxin has demonstrated the ability to produce antibodies against Covid-19. However, the clinical efficacy of Covaxin is yet to be established and it is still being studied in phase 3 clinical trial.

In phase 1 and 2 trials, 680 people were administered two doses each of Covaxin. The phase 3 clinical trial with 25,800 participants is on. The first dose was administered to them on January 6.

In the ongoing clinical trial, Covaxin has shown to generate immunity following two doses given four weeks apart, the firm said.

Covaxin, which Bharat Biotech developed in collaboration with the Indian Council of Medical Research and National Institute of Virology, and 'Covishield', developed by Oxford University and pharmaceutical company AstraZeneca and manufactured by Serum Institute of India at Pune, have been cleared by the DCGI for emergency use. Both the vaccines are in use during the nationwide immunisation programme launched on January 16.

The move to include Covaxin even before the publication of data from its phase 3 trial had come under criticism from some quarters. However, the regulator had defended the decision by saying that both the vaccines were totally safe.

Over 500 adverse reactions were reported from across the country during two days of immunisation. Two deaths were also reported but the government clarified that these were not related to vaccination.

Bharat Biotech said in case of any Serious Adverse Events (SAV), vaccine recipients will be provided medically recognised standards of care in government-designated and authorised centers/hospitals. Compensation for serious adverse event will be paid by Bharat Biotech International Limited and if SAV is proved to be casually related to the vaccine. The compensation amount will be determined by the ICMR Central Ethics Committee, it added.

--IANS ms/tsb

( 525 Words)

2021-01-19-13:04:05 (IANS)

 
  LATEST COMMENTS ()
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
 
MORE HEALTH NEWS
UK reports big rise in mental health iss...
Odisha allows Jatra shows with cap of 2,...
S. Korea: Innovative syringe to increase...
1st batch of MBBS students inaugurated a...
Andhra registers 118 more Covid infectio...
Here's how exercise may benefit older ad...
More...
 
INDIA WORLD ASIA
Uttarakhand: Legal action to be taken ag...
Tamil Nadu Assembly polls: PMK to contes...
TRS President says BJP, Congress have no...
BJP can't threaten me by sending ED, CBI...
Bengal first among 5 poll-bound states i...
In Assam 46.93% believe living standards...
More...    
 
 Top Stories
Centre to launch campaign to promot... 
Taapsee Pannu celebrates one year o... 
SLC appoints Mathews as stand-in T2... 
DCW demands action taken report fro... 
Rakesh Tikait to hold Kisan Mahapan... 
CSA announces 17-member women's squ... 
WB polls: 3,064 booths designated f... 
Armenian president rejects prime mi...